Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Net (2013 - 2024)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Receivables - Net came in at $14000.0 in Q3 2024, down 86.27% year-on-year from $102000.0 in Q4 2023, and down 86.27% quarter-over-quarter from $102000.0 in Q1 2024.
Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Net (2013 - 2024) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Receivables - Net history runs 12 years deep, the most recent figure standing at $14000.0 for Q3 2024.
- On a quarterly basis, Receivables - Net fell 86.27% year-over-year to $14000.0 in Q3 2024; TTM through Sep 2024 was $14000.0, a 86.27% decrease from a year earlier, with the FY2023 full-year figure at $102000.0, changed 0.0% from the prior year.
- Receivables - Net retreated to $14000.0 in Q3 2024 per VRDN's latest filing, from $102000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $1.0 million in Q3 2021 and bottomed at $4000.0 in Q1 2020.
- The 5-year median for Receivables - Net is $102000.0 (2022), against an average of $268333.3.
- Across the five-year window, Receivables - Net tumbled 94.18% in 2020 and jumped 1654.39% in 2021, its largest moves.
- Year by year, Receivables - Net stood at $57000.0 in 2020, then soared by 691.23% to $451000.0 in 2021, then slumped by 77.38% to $102000.0 in 2022, then changed by 0.0% to $102000.0 in 2023, then tumbled by 86.27% to $14000.0 in 2024.
- Per Business Quant, the three latest VRDN Receivables - Net figures stand at $14000.0 (Q3 2024), $102000.0 (Q1 2024), and $102000.0 (Q4 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Sep 30, 2023 | 102,000.00 |
| Sep 30, 2023 | 102,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Mar 31, 2023 | 128,000.00 |
| Mar 31, 2023 | 128,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Sep 30, 2022 | 398,000.00 |
| Sep 30, 2022 | 398,000.00 |
| Jun 30, 2022 | 693,000.00 |
| Jun 30, 2022 | 693,000.00 |
| Mar 31, 2022 | 522,000.00 |
| Mar 31, 2022 | 522,000.00 |